Reliable Antibodies for Immunology Research: TREM1 as a Case Study of Abcam’s Enhanced Validation Framework 2307284

Abstract

Abstract Introduction Reliable antibody performance is essential for translational research, particularly when investigating disease-associated targets such as, Triggering Receptor Expressed on Myeloid Cells 1 (TREM1), a key modulator of innate immune responses implicated in inflammatory conditions. Conventional antibody validation methods often fall short in addressing the complexity of human tissue expression and disease heterogeneity. Methods To overcome these limitations, an enhanced validation framework was developed that integrates disease-relevant tissue profiling. This approach combines multiple validation steps, including specificity testing and generating detailed IHC expression profiles in selected formalin- fixed paraffin-embedded (FFPE) human tissue microarrays (TMA) using automated immunohistochemistry (IHC) platforms. As a case study, a recombinant rabbit monoclonal antibody (RabMab®) targeting TREM1, clone EPR22060-229 (ab225861), was validated across multiple IHC automated platforms. Results In both normal and cancer tissues, the antibody showed positive staining in interstitial regions and infiltrating lymphocytes. Its high specificity was further validated through co-localization assays with CD14, a well-established myeloid marker, across COVID-19, glioblastoma, and inflammatory bowel disease (IBD) samples, confirming accurate detection of TREM1-expressing cells. Conclusion This study highlights the value of enhanced antibody validation in de-risking reagent selection and ensuring robust, reproducible results in translational research. The TREM1 case exemplifies how rigorous Abcam’s antibody validation can accelerate discovery and translational applications. Funding Source n/a Topic Categories Cellular Adhesion, Migration, and Inflammation (CAM)